# US 2008/0305552 A1 · Assays for preimplantation factor and preimplantation factor peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305552 A1
- Document ID: US20080305552A1
- Status: Published application
- Kind: A1
- Application number: 11/855,616
- Filed: 2007-09-14
- Published: 2008-12-11
- Earliest claimed: 2001-07-02
- Assignees: Bioincept, LLC
- Inventors: Eytan R. Barnea; Ruben Rene Gonzales Perez; Paul C. Leavis
- Web page: https://patentgrep.com/patent/US20080305552A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- C07K 14/4715: {Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein}
- G01N 33/689: {related to pregnancy or the gonads}
- G01N 2333/70507: C2D
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytometry assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled anti-lymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (i) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate.

## Claims

### Claim 1

An isolated peptide which binds to anti-CD2 antibody, said isolated peptide comprising the sequence selected from the group of Ser-Gln-Ala-Val-Gln-Glu-His-Ala-Ser-Thr (SEQ ID No. 7) and Ser-Gln-Ala-Val-Gln-Glu-His-Ala-Ser-Thr-Asn-Xaa-Gly (SEQ ID No. 8), wherein Xaa can be any amino acid.

### Claim 2 (depends on 1)

The isolated peptide of claim 1, wherein said isolated peptide comprises Ser-Gln-Ala-Val-Gln-Glu-His-Ala-Ser-Thr (SEQ ID No. 7).

### Claim 3 (depends on 1)

The isolated peptide of claim 1, wherein said isolated peptide comprises Ser-Gln-Ala-Val-Gln-Glu-His-Ala-Ser-Thr-Asn-Xaa-Gly (SEQ ID No. 8), wherein Xaa can be any amino acid.

### Claim 4

A method of determining embryo viability in a subject comprising detecting the presence of a peptide comprising the sequence selected from the group of Ser-Gln-Ala-Val-Gln-Glu-His-Ala-Ser-Thr (SEQ ID No. 7) and Ser-Gln-Ala-Val-Gln-Glu-His-Ala-Ser-Thr-Asn-Xaa-Gly (SEQ ID No. 8), wherein Xaa can be any amino acid.

### Claim 5 (depends on 4)

The method of claim 4, wherein the presence of said peptide is detected in a sample selected from sera and embryo culture media.

### Claim 6

A method of detecting pregnancy in a subject comprising detecting the presence of a peptide comprising the sequence selected from the group of Ser-Gln-Ala-Val-Gln-Glu-His-Ala-Ser-Thr (SEQ ID No. 7) and Ser-Gln-Ala-Val-Gln-Glu-His-Ala-Ser-Thr-Asn-Xaa-Gly (SEQ ID No. 8), wherein Xaa can be any amino acid.

### Claim 7 (depends on 6)

The method of claim 6, wherein the presence of said peptide is detected in sera.
